Members Podcast
Market surviving the CPI number overnight – all is not lost although the rally has certainly started to doubt itself.
BOQ – Cheap Post Results But Should You Buy?
BOQ released full year results on Wednesday and was received poorly by the market to say the least. Down 7% (a lot for a bank) on the news, followed by an interesting bounce back yesterday, up 4%.
End of Day Report Friday
ASX 200 performs better than expected, falling only 40 points to 7051 (-0.6%). Volumes seemed light, and some book squaring ahead of US results helped sentiment. Banks eased back, with CBA down 0.6% and the Big Bank Basket down to $177.48 (-0.7%). Insurers slightly better IAG up 0.2%. Fund managers eased back, and REITs fell back as 10-year yields…
Henry’s Take – A Pause to Refresh?
SMALL CAP PORTFOLIO 3.00pm Updates Nothing done today. Selected lithium stocks recovering from oversold levels. PMT, CXO, AZS to name a few. Market impetus running out as US CPI approaches. Volumes in small caps remain low. CSL a major drag as US Med tech under pressure on new kidney trial results using the ‘miracle’ weight…
Marcus Take
Buy signals on the All Ordinaries, ASX 200, S&P 500 and Nasdaq are now 4 days old. There are now MACD buy signals as well. Telstra (TLS) weekly buy signal. Again. Not often traded by Australians – but there’s a buy signal on SQ2. Qantas (QAN), anyone?. Very early short-term buy signal after dropping from 670c to 490c over the Qatar debacle (not their fault).
Members Podcast Thursday – Waiting for tonight’s CPI number
Our market up again – we are four days into this rally with the US CPI number to worry about tonight
Marcus Take – The Doves are still flapping
The Doves are still flapping – we are four days into this market rally
CBA update post AGM – No new news
CBA had its AGM yesterday – the share price dropped 0.31% (hardly changed), with one broker saying there was "No new news". A fairly quiet affair. Just a lot of motherhood comments about assisting the cost of living pressures, holding a strong balance sheet, and remaining well placed heading into a lower growth environment. There…
CSL AGM Update – Market didn’t like it
CSL fell 6.3% today continuing its nasty downtrend, as the GLP-1 (obesity drugs) juggernaut continues to smash through the healthcare sector. It has already destroyed ResMed (RMD) and yesterday their five year study into the GLP-1 efficacy in treating chronic kidney disease and Type 2 diabetes was halted early because the results were so good. It is…
End of Day Report Thursday
ASX 200 limped to a 3-point gain to 7091 (+0.04%) ahead of US CPI. Six sessions in a row. Just. CSL was the biggest drag on the index as positive drug trials in the US marred the outlook for medical companies. The stock fell 6.3%, RMD down 5.3% on the same effect. Banks once again…